The U.S. Food and Drug Administration (FDA) has approved the use of Wandercraft's Atalante exoskeleton for the rehabilitation of stroke patients with walking problems.
The Atalante is a self-balancing, walk-adjustable device that will aid in the recovery of walking skills as part of rehabilitation therapy. Rehabilitation with Atalante must be done in a clinic setting in the presence of a physician. It doesn't matter how much mobility the patient has after the stroke to use the device.
Wandercraft plans to deliver the first exoskeletons in the U.S. during the first quarter of the year. The company recently began commercial use of its equipment in the country. According to its investor, Quadrant Management, Wandercraft has the ability to significantly increase exoskeleton production within 1-2 years.
More than 795,000 people in the U.S. suffer strokes each year, and Wandercraft Atalante can help some of them regain the ability to get around independently, without the use of a wheelchair.